

Preferred Drug List Announcement

MO HealthNet Division (MHD) is continuing the state-specific Preferred Drug List (PDL) evaluation process. Drugs/Drug classes for review for the upcoming quarter are identified at each of the quarterly meetings of the Drug Prior Authorization Committee.

MO HealthNet Division's clinical team will conduct the clinical reviews of the drug products under evaluation each quarter. For preferred status consideration for your product, a more detailed review request should be presented to MHD.

- All clinical information for consideration should be forwarded to Karen Powell at karen.powell@gainwelltechnologies.com. These submissions should generally follow the AMCP guideline format.
- Financial evaluations for these therapeutic class reviews are conducted by Gainwell Technologies, LLC. Companies wishing to discuss opportunities for supplemental rebates and/or the policy surrounding the PDL process should contact GWTContracting@gainwelltechnologies.com and Sandy Kapur, PharmD at sandy.kapur@gainwelltechnologies.com.
- If a public presentation is desired, please contact Carmen Burton at Carmen.M.Burton@dss.mo.gov or call (573) 751-6961.

The Drug PA Committee will convene at 10:00 a.m. on Tuesday, July 18, 2023.

Drug Therapeutic Class Name
Central Nervous System
<ul style="list-style-type: none"> • Multiple Sclerosis Agents, Injectable • Multiple Sclerosis Agents, Oral
Dermatologic Agents
<ul style="list-style-type: none"> • Oral Agents for Psoriasis • Topical Agents for Psoriasis • Topical Immunomodulators for Atopic Dermatitis
Endocrine and Metabolic Agents
<ul style="list-style-type: none"> • Antihyperglycemic, Alpha Glucosidase Inhibitors • Antihyperglycemic, Amylin-analogs • Antihyperglycemic, Biguanides and Combinations • Antihyperglycemic, DPP-IV Inhibitors and Combinations • Antihyperglycemic, GLP-1 Receptor Agonists and Combinations • Antihyperglycemic, Insulin – Long-acting Analogs • Antihyperglycemic, Insulin – Mixed • Antihyperglycemic, Insulin – Non-analogs

Drug Therapeutic Class Name
<ul style="list-style-type: none"> • Antihyperglycemic, Insulin – Rapid-acting • Antihyperglycemic, Meglitinides • Antihyperglycemic, SGLT-2 Inhibitors and Combinations • Antihyperglycemic, Sulfonylureas (Oral), 2nd Generation • Antihyperglycemic, Thiazolidinediones and Combinations • Growth Hormones and Growth Hormone Releasing Factors, Select Agents • Growth Hormones, Somatropin Agents • LHRH, GnRH Antagonists, Injectable • LHRH, GnRH Antagonists, Oral
Hematological Agents
<ul style="list-style-type: none"> • Agents for Bleeding Disorders • Agents for Thrombocytopenia • Erythropoiesis Stimulating Agents • Leukocyte (White Blood Cell) Stimulating Agents
Immunologic Agents
<ul style="list-style-type: none"> • Systemic Immunomodulators, Cryopyrin-Associated Periodic Syndrome (CAPS) Agents • Targeted Immune Modulators, IL-6 Receptor Inhibitors • Targeted Immune Modulators, IL-17A Antibody/IL-17 Receptor Antagonists • Targeted Immune Modulators, IL-23 and IL-23/IL-12 Inhibitors • Targeted Immune Modulators, JAK Inhibitors • Targeted Immune Modulators, Misc Allergy and Asthma-related Monoclonal Antibodies • Targeted Immune Modulators, Select Agents • Targeted Immune Modulators, TNF Inhibitors
Miscellaneous
<ul style="list-style-type: none"> • Methotrexate Products
Renal and Genitourinary
<ul style="list-style-type: none"> • Urinary Tract Antispasmodics